PT687176E - Aplicacao de riluzol no tratamento da neuro-sida - Google Patents
Aplicacao de riluzol no tratamento da neuro-sida Download PDFInfo
- Publication number
- PT687176E PT687176E PT94908374T PT94908374T PT687176E PT 687176 E PT687176 E PT 687176E PT 94908374 T PT94908374 T PT 94908374T PT 94908374 T PT94908374 T PT 94908374T PT 687176 E PT687176 E PT 687176E
- Authority
- PT
- Portugal
- Prior art keywords
- riluzole
- preparation
- neuro
- application
- medicaments
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 208000030507 AIDS Diseases 0.000 title claims abstract description 7
- 229960004181 riluzole Drugs 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- 230000016273 neuron death Effects 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 206010060860 Neurological symptom Diseases 0.000 claims description 2
- 208000022873 Ocular disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 244000096108 cunha Species 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000006576 neuronal survival Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940096364 riluzole 50 mg Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- -1 methyl hydroxypropyl Chemical group 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
86 006
ΕΡ 0 687 176/PT
DESCRIÇÃO “Aplicação de riluzol no tratamento da neuro-SIDA” O presente invento refere-se a uma nova aplicação do riluzol ou dos sais farmaceuticamente aceitáveis deste composto. O riluzol ou os seus sais farmaceuticamente aceitáveis são descritos como anti-convulsivos e anti-epilépticos, designadamente na patente EP 50551.
Foi recentemente verificado, duma forma surpreendente, que este composto pode também ser utilizado no tratamento da neuro-SIDA. O termo neuro-SIDA abrange os distúrbios mentais, os distúrbios cognitivos, as neuropatias, as miopatias, os distúrbios oculares e todos os sintomas neurológicos ligados ao vírus HIV-1. A actividade do riluzol na neuro-SIDA foi posta em evidência no ensaio da morte neuronal induzida pela proteína GP-120, proteína do revestimento do vírus HIV-1, segundo o protocolo seguinte:
Preparam-se culturas de células corticais segundo o método descrito por SINDOU et al., Brain Res., 572, 242-246 (1992). Após 8 a 10 dias de cultura, os neurónios que adquiriram uma forma neurítica correcta são utilizados para os ensaios. As células são guardadas a 37°C numa estufa de CO2 para 0 conjunto da experiência. A sobrevivência neuronal é avaliada antes e após 24 horas de aplicação do produto a ensaiar por uma técnica colorimétrica com Azul de Tuspan contando campos predeterminados (método semi-quantitativo). Foi analisado um mínimo de 4 caixas de cultura por concentração (100 neurónios por caixa).
Numa primeira série, foi determinada a sobrevivência neuronal do meio de cultura sem nenhum produto. A sobrevivência neuronal foi então de cerca de 87%.
Numa segunda série, foi posta em evidência a toxicidade da GP-120 em cultura. A GP-120 foi aplicada isolada sobre o meio de cultura durante 24 horas, a uma concentração de 20 pmol, e conduz à morte neuronal da ordem dos 43%.
86 006
ΕΡ 0 687 176/PT 2
Na terceira série, o produto a ensaiar em solução no dimetilsulfóxido (10‘3M) foi aplicado 5 minutos antes da aplicação da GP-120 e incubado em seguida durante 24 horas, em concentrações desde 10’7 até IO'8 mol. Os resultados obtidos são os seguintes: SERIE 1 SERIE 2 SERIE 3 TESTEMUNHAS SOBREVIVÊNCIA SOBREVIVÊNCIA SOBREVIVÊNCIA NEURONAL NEURONAL NEURONAL GP120 SÓ GP120 E RILUZOL (20 pmol) (10'T MOL) 87,2±7,2% 57,3±9,1% 80,6±9,9%
Como sais farmaceuticamente aceitáveis podem ser citados, designadamente, os sais de adição com os ácidos minerais tais como cloridrato, sulfato, nitrato, fosfato, ou orgânicos tais como acetato, propionato, succinato, oxalato, benzoato, fumarato, maleato, metanossulfonato, isotionato, teofilino-acetato, salicilato, fenolftaleinato, metileno-bis-β-oxinaftoato ou derivados de substituição destes derivados.
Os medicamentos são constituídos por pelo menos o riluzol sob forma livre ou sob a forma de um sal de adição com um ácido farmaceuticamente aceitável, no estado puro ou sob a forma de uma composição onde aquele está associado a qualquer outro produto compatível farmaceuticamente. podendo ser inerte ou fisiologicamente activo. Os medicamentos segundo o invento podem ser utilizados por via oral ou parentérica.
Como composições sólidas para administração oral, podem ser utilizados comprimidos, pílulas, pós (cápsulas de gelatina, hóstias) ou granulados. Nestas composições, o princípio activo segundo o invento é misturado com um ou vários diluentes inertes, como o amido, celulose, sacarose, lactose ou sílica, sob corrente de árgon. Estas composições podem igualmente compreender outras substâncias para além dos diluentes, por exemplo um ou mais lubrificantes como o estearato de magnésio ou o talco, um corante, um invólucro (drageias) ou um vemiz.
Como composições líquidas para administração oral, podem utilizar-se soluções, suspensões, emulsões, xaropes e elixires farmaceuticamente aceitáveis contendo diluentes inertes tais como água, etanol. glicerol. óleos vegetais ou óleo de parafina. Estas composições podem compreender outras substâncias além dos diluentes, por exemplo produtos molhantes, edulcorantes. espessantes, aromatizantes ou estabilizantes.
86 006
ΕΡ 0 687 176/PT 3
Os componentes estéreis para administração parentérica podem ser de preferência soluções aquosas ou não aquosas, suspensões ou emulsões. Como solvente ou veículo, pode utilizar-se água, propilenoglicol, polietilenoglicol, óleos vegetais, em particular azeite de oliveira, ésteres orgânicos injectáveis, por exemplo oleato de etilo ou outros solventes orgânicos convenientes. Estas composições podem igualmente conter adjuvantes, em particular agentes molhantes, isotonizantes, emulsionantes, dispersantes e estabilizantes. A esterilização pode fazer-se de várias maneiras, por exemplo por filtração asséptica, incorporando na composição agentes esterilizantes, por irradiação ou por aquecimento. Podem igualmente ser preparadas sob a forma de composições sólidas estéreis que podem ser dissolvidas no momento de emprego em água esterilizada ou qualquer outro meio estéril injectável.
As doses dependem do efeito desejado, da duração do tratamento e da via de administração utilizada; estão geralmente compreendidas entre 50 e 400 mg por dia, por via oral para adulto, com doses unitárias que vão de 25 a 200 mg de princípio activo.
Dum modo geral, o médico determinará a posologia apropriada em função da idade, do peso e de todos os outros factores próprios do paciente a tratar.
Os exemplos seguintes ilustram os medicamentos segundo o invento:
Exemplo A
Preparam-se, segundo a técnica habitual, comprimidos doseados a 50 mg de produto activo, com a composição seguinte: - Riluzol 50 mg - Manitol 64 mg - Celulose microcristalina 50 mg - Excipiente de polividona 12 mg - Carboximetilamido sódico 16 mg - Talco 4 mg - Estearato de magnésio 2 mg - Sílica coloidal anidra 2 mg - Mistura de metil-hidroxipropilcelulose, polietilenoglicol 6000, dióxido de titânio (72-3,5-24,5) q.b.p. 1 comprimido revestido terminado a 245 mg 86 006 EP 0 687 176/PT 4 Exemolo B Preparam-se, segundo a técnica habitual, cápsulas de gelatina doseadas a 50 mg de produto activo, com a seguinte composição: - Riluzol 50 mg - Celulose 18 mg - Lactose 55 mg - Sílica coloidal 1 mg - Carboximetilamido sódico 10 mg - Talco 10 mg - Estearato de magnésio 1 mg
Exemplo C Prepara-se uma solução injectável contendo 10 mg de produto activo, com a composição seguinte: - Riluzol 10 mg - Ácido benzóico 80 mg - Álcool benzílico 0,06 cm3 - Benzoato de sódio 80 mg - Etanol a 95% 0,4 cmJ - Hidróxido de sódio 24 mg - Propilenoglicol l ,6 cm3 - Água q.b.p. 4 cmJ O invento refere-se igualmente ao processo de preparação de medicamentos úteis no tratamento da neuro-SIDA, que consiste em misturar o riluzol ou os sais faimaceuticamente aceitáveis deste composto com um ou mais diluentes e/ou adjuvantes compatíveis e farmaceuticamente aceitáveis.
Lisboa, 3l. MAI 2001
Por AVENTIS PHARMA S.A. -O A(
gA CUNHA FERREIRÀ Ag. Of. Pr. Ιης). Rua das Flores, 74-4.° 1200-195 LISBOA
Claims (4)
- 86 006 ΕΡ 0 687 176/PT 1/1 REIVINDICAÇÕES 1. Aplicação do riluzol, ou dos seus sais farmaceuticamente aceitáveis, à preparação de medicamentos destinados ao tratamento da neuro-SIDA.
- 2. Aplicação, de acordo com a reivindicação 1, à preparação de medicamentos destinados ao tratamento de distúrbios mentais, de distúrbios cognitivos, de neuropatias, da miopatia, de distúrbios oculares e de todos os sintomas neurológicos ligados ao vírus HIV-1.
- 3. Aplicação, de acordo com a reivindicação 1, para a obtenção de um medicamento que compreende de 25 a 200 mg de riluzol.
- 4. Aplicação do riluzol, ou dos sais farmaceuticamente aceitáveis deste composto, à preparação de medicamentos destinados a diminuir a morte neuronal induzida pela proteína GP-120". Lisboa, 31. MM 2001 Por AVENTIS PHARMA S.A. - O AGENTE OFICIAL -Eng.° ANTÓNIO iOlO DA CUNHA FERRE1RA Ag. 0{. Pr. Ind. Rua das Flores, 74--4.0 1200*195 LISBOA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9302568A FR2702148B1 (fr) | 1993-03-05 | 1993-03-05 | Application d'anticonvulsivants dans le traitement du neuro-sida. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT687176E true PT687176E (pt) | 2001-09-28 |
Family
ID=9444690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT94908374T PT687176E (pt) | 1993-03-05 | 1994-02-25 | Aplicacao de riluzol no tratamento da neuro-sida |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US5629312A (pt) |
| EP (3) | EP0687179A1 (pt) |
| JP (3) | JPH08507508A (pt) |
| KR (3) | KR960700721A (pt) |
| AT (2) | ATE147981T1 (pt) |
| AU (3) | AU6143894A (pt) |
| CA (3) | CA2154572C (pt) |
| CZ (3) | CZ226095A3 (pt) |
| DE (2) | DE69427344T2 (pt) |
| DK (2) | DK0687176T3 (pt) |
| ES (2) | ES2157252T3 (pt) |
| FR (1) | FR2702148B1 (pt) |
| GR (2) | GR3022356T3 (pt) |
| HU (3) | HUT73434A (pt) |
| IL (3) | IL108845A0 (pt) |
| NO (3) | NO953372L (pt) |
| PL (3) | PL310475A1 (pt) |
| PT (1) | PT687176E (pt) |
| RU (1) | RU2157205C2 (pt) |
| SK (3) | SK107495A3 (pt) |
| UA (1) | UA41355C2 (pt) |
| WO (3) | WO1994020110A1 (pt) |
| ZA (2) | ZA941530B (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866597A (en) * | 1993-03-19 | 1999-02-02 | Glaxo Wellcome Inc. | Use of triazine compounds for the treatment of memory and learning disorders |
| GB9424766D0 (en) * | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
| GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
| DE19603984A1 (de) * | 1996-02-05 | 1997-08-07 | Bayer Ag | Granulate von Triazinen |
| CO4920215A1 (es) * | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| US20020022056A1 (en) | 1997-02-14 | 2002-02-21 | Burkhard Schlutermann | Oxacarbazepine film-coated tablets |
| US5922746A (en) * | 1997-03-27 | 1999-07-13 | Allergan | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
| GB9721497D0 (en) * | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
| FR2774592B1 (fr) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet |
| FR2774908B1 (fr) * | 1998-02-17 | 2000-06-23 | Centre Nat Rech Scient | Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne |
| FR2787028B1 (fr) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | Utilisation du riluzole dans le traitement des traumatismes acoustiques |
| AU4424500A (en) * | 1999-04-29 | 2000-11-17 | Centre National De La Recherche Scientifique (C.N.R.S.) | A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping |
| US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
| GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| FR2801217B1 (fr) * | 1999-11-24 | 2002-12-06 | Aventis Pharma Sa | Association de riluzole et de gabapentine et son utilisation comme medicament |
| GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| US6207179B1 (en) * | 2000-05-18 | 2001-03-27 | Phoenix Scientific, Inc. | Parasiticidal formulation for animals and a method of making this formulation |
| CA2471666C (en) | 2004-06-18 | 2009-10-13 | Apotex Pharmachem Inc. | An improved process for the preparation of oxcarbazepine and related intermediates |
| SI2982372T1 (sl) * | 2005-04-05 | 2020-11-30 | Yale University, Office of Cooperative Research | Sredstva za modulacijo glutamata pri zdravljenju mentalnih motenj |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| FR2910811B1 (fr) * | 2007-01-03 | 2009-07-10 | Ass Pour Le Dev De La Biothera | Utilisation du riluzole et de ses derives pour fabriquer de nouveaux medicaments |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| EP3616686B8 (en) * | 2014-11-21 | 2021-06-23 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual formulation of riluzole |
| EP4298191A4 (en) * | 2021-02-24 | 2024-07-03 | Vgp Ipco Llc | FOAMING EVAPORATOR COIL CLEANER |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US4431641A (en) * | 1980-10-17 | 1984-02-14 | Ciba-Geigy Corporation | Pharmaceutical compositions having antiepileptic and antineuralgic action |
| GB8613183D0 (en) * | 1986-05-30 | 1986-07-02 | Wellcome Found | Triazine salt |
| US4826860A (en) * | 1987-03-16 | 1989-05-02 | Warner-Lambert Company | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents |
| FR2619713B1 (fr) * | 1987-08-25 | 1990-08-31 | Rhone Poulenc Sante | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression |
| FR2619712B1 (fr) * | 1987-08-25 | 1990-08-31 | Rhone Poulenc Sante | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la schizophrenie |
| US4918090A (en) * | 1988-01-25 | 1990-04-17 | Warner-Lambert Company | Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents |
| EP0435826A1 (de) * | 1989-12-27 | 1991-07-03 | Ciba-Geigy Ag | Intravenöse Lösungen für Status Epilepticus |
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| JPH07308499A (ja) * | 1994-05-20 | 1995-11-28 | Brother Ind Ltd | 衣類乾燥機 |
-
1993
- 1993-03-05 FR FR9302568A patent/FR2702148B1/fr not_active Expired - Lifetime
-
1994
- 1994-02-25 WO PCT/FR1994/000209 patent/WO1994020110A1/fr not_active Application Discontinuation
- 1994-02-25 PL PL94310475A patent/PL310475A1/xx unknown
- 1994-02-25 SK SK1074-95A patent/SK107495A3/sk unknown
- 1994-02-25 CA CA002154572A patent/CA2154572C/fr not_active Expired - Fee Related
- 1994-02-25 KR KR1019950703734A patent/KR960700721A/ko not_active Withdrawn
- 1994-02-25 AU AU61438/94A patent/AU6143894A/en not_active Abandoned
- 1994-02-25 HU HU9502583A patent/HUT73434A/hu unknown
- 1994-02-25 AT AT94908376T patent/ATE147981T1/de active
- 1994-02-25 CA CA002154573A patent/CA2154573A1/fr not_active Abandoned
- 1994-02-25 AU AU61439/94A patent/AU675119B2/en not_active Ceased
- 1994-02-25 SK SK1076-95A patent/SK279659B6/sk not_active IP Right Cessation
- 1994-02-25 DK DK94908374T patent/DK0687176T3/da active
- 1994-02-25 WO PCT/FR1994/000210 patent/WO1994020108A1/fr active IP Right Grant
- 1994-02-25 PL PL94310474A patent/PL310474A1/xx unknown
- 1994-02-25 RU RU95121731/14A patent/RU2157205C2/ru not_active IP Right Cessation
- 1994-02-25 ES ES94908374T patent/ES2157252T3/es not_active Expired - Lifetime
- 1994-02-25 JP JP6519648A patent/JPH08507508A/ja active Pending
- 1994-02-25 CA CA002154571A patent/CA2154571A1/fr not_active Abandoned
- 1994-02-25 AT AT94908374T patent/ATE201597T1/de active
- 1994-02-25 EP EP94908375A patent/EP0687179A1/fr not_active Withdrawn
- 1994-02-25 CZ CZ952260A patent/CZ226095A3/cs unknown
- 1994-02-25 CZ CZ952261A patent/CZ284423B6/cs unknown
- 1994-02-25 JP JP51964794A patent/JP3578174B2/ja not_active Expired - Fee Related
- 1994-02-25 SK SK1075-95A patent/SK107595A3/sk unknown
- 1994-02-25 HU HU9502585A patent/HU217132B/hu not_active IP Right Cessation
- 1994-02-25 EP EP94908376A patent/EP0687177B1/fr not_active Expired - Lifetime
- 1994-02-25 KR KR1019950703732A patent/KR100318168B1/ko not_active Expired - Fee Related
- 1994-02-25 DE DE69427344T patent/DE69427344T2/de not_active Expired - Lifetime
- 1994-02-25 DK DK94908376.0T patent/DK0687177T3/da active
- 1994-02-25 JP JP6519649A patent/JPH08507509A/ja active Pending
- 1994-02-25 PT PT94908374T patent/PT687176E/pt unknown
- 1994-02-25 WO PCT/FR1994/000208 patent/WO1994020103A1/fr active IP Right Grant
- 1994-02-25 ES ES94908376T patent/ES2096455T3/es not_active Expired - Lifetime
- 1994-02-25 PL PL94310476A patent/PL310476A1/xx unknown
- 1994-02-25 KR KR1019950703733A patent/KR960700723A/ko not_active Withdrawn
- 1994-02-25 UA UA95083996A patent/UA41355C2/uk unknown
- 1994-02-25 US US08/530,253 patent/US5629312A/en not_active Expired - Fee Related
- 1994-02-25 EP EP94908374A patent/EP0687176B1/fr not_active Expired - Lifetime
- 1994-02-25 CZ CZ952259A patent/CZ285339B6/cs not_active IP Right Cessation
- 1994-02-25 HU HU9502584A patent/HU9502584D0/hu unknown
- 1994-02-25 AU AU61437/94A patent/AU675118B2/en not_active Ceased
- 1994-02-25 DE DE69401577T patent/DE69401577T2/de not_active Expired - Fee Related
- 1994-03-03 IL IL10884594A patent/IL108845A0/xx unknown
- 1994-03-03 IL IL10884694A patent/IL108846A0/xx not_active IP Right Cessation
- 1994-03-03 IL IL108844A patent/IL108844A/en not_active IP Right Cessation
- 1994-03-04 ZA ZA941530A patent/ZA941530B/xx unknown
- 1994-03-04 ZA ZA941525A patent/ZA941525B/xx unknown
-
1995
- 1995-02-28 US US08/396,106 patent/US5624945A/en not_active Expired - Lifetime
- 1995-08-28 NO NO953372A patent/NO953372L/no unknown
- 1995-08-28 NO NO953371A patent/NO953371L/no unknown
- 1995-08-28 NO NO953370A patent/NO307687B1/no not_active IP Right Cessation
-
1997
- 1997-01-23 GR GR960402768T patent/GR3022356T3/el unknown
-
2001
- 2001-05-31 GR GR20010400060T patent/GR3035957T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT687176E (pt) | Aplicacao de riluzol no tratamento da neuro-sida | |
| JP2713384B2 (ja) | ２‐アミノ‐６‐（トリフルオロメトキシ）‐ベンゾチアゾール（リルゾール）の運動ニューロン疾患の処置を意図した医薬を得るための使用 | |
| RU2221563C2 (ru) | Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона | |
| IE904226A1 (en) | Stabilized solutions of psychotropic agents | |
| KR20070084123A (ko) | 양극성 장애 및 관련 증상의 치료 | |
| JP2006511538A (ja) | 非ヌクレオシド系逆転写酵素阻害剤（ｎｎｒｔｉ）とプロテアーゼ阻害剤などのシトクロムｐ４５０の阻害剤とを含む組み合わせの使用 | |
| PT738147E (pt) | Aplicacao do riluzolo no tratamento das doencas mitocondriais | |
| KR930007252B1 (ko) | 우울증 치료용 약학조성물 | |
| ES2214305T3 (es) | Utilizacion de la ciamemazina en el tratamiento de la eliminacion brusca de las benzodiazepinas. | |
| JPWO2004017973A1 (ja) | 統合失調症治療剤 | |
| EP0300073A1 (en) | Use of fusidic acid in the treatment of aids-related complex and full-blown aids | |
| US5886000A (en) | Anti-HIV agent | |
| JP2003055227A (ja) | 安定化された組成物 | |
| JP2003055224A (ja) | 安定化された組成物 | |
| JP2003055221A (ja) | 安定化された組成物 | |
| AU761978B2 (en) | Use of 2-amino-6- trifluoromehthoxy- benzothiazole for preventing or treating cerebellum dysfunction |